AU2020394374A1 - CELA-1 inhibition for treatment of lung disease - Google Patents

CELA-1 inhibition for treatment of lung disease Download PDF

Info

Publication number
AU2020394374A1
AU2020394374A1 AU2020394374A AU2020394374A AU2020394374A1 AU 2020394374 A1 AU2020394374 A1 AU 2020394374A1 AU 2020394374 A AU2020394374 A AU 2020394374A AU 2020394374 A AU2020394374 A AU 2020394374A AU 2020394374 A1 AU2020394374 A1 AU 2020394374A1
Authority
AU
Australia
Prior art keywords
residues
cela1
lung
antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020394374A
Other languages
English (en)
Other versions
AU2020394374A9 (en
Inventor
Brian VARISCO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of AU2020394374A1 publication Critical patent/AU2020394374A1/en
Publication of AU2020394374A9 publication Critical patent/AU2020394374A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21036—Pancreatic elastase (3.4.21.36)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020394374A 2019-11-26 2020-11-23 CELA-1 inhibition for treatment of lung disease Pending AU2020394374A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940302P 2019-11-26 2019-11-26
US62/940,302 2019-11-26
US202063009134P 2020-04-13 2020-04-13
US63/009,134 2020-04-13
PCT/US2020/061774 WO2021108302A1 (en) 2019-11-26 2020-11-23 Cela-1 inhibition for treatment of lung disease

Publications (2)

Publication Number Publication Date
AU2020394374A1 true AU2020394374A1 (en) 2022-06-02
AU2020394374A9 AU2020394374A9 (en) 2022-06-16

Family

ID=76129647

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020394374A Pending AU2020394374A1 (en) 2019-11-26 2020-11-23 CELA-1 inhibition for treatment of lung disease

Country Status (6)

Country Link
US (1) US20230002510A1 (enExample)
EP (1) EP4065167A4 (enExample)
JP (1) JP2023502259A (enExample)
AU (1) AU2020394374A1 (enExample)
IL (1) IL293238A (enExample)
WO (1) WO2021108302A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646160A (zh) * 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CN107690429B (zh) * 2015-04-07 2022-02-25 Ela制药有限公司 用于治疗和/或预防细胞或组织坏死的组合物，其特异性靶向组织蛋白酶c和/或cela1和/或cela3a和/或与其结构相关的酶
EP3737666A4 (en) * 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES

Also Published As

Publication number Publication date
US20230002510A1 (en) 2023-01-05
JP2023502259A (ja) 2023-01-23
IL293238A (en) 2022-07-01
WO2021108302A1 (en) 2021-06-03
EP4065167A4 (en) 2024-03-27
AU2020394374A9 (en) 2022-06-16
EP4065167A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
CA2759129C (en) Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
CN117503923A (zh) 用于抑制有需要的受试者的纤维化的方法
EP1135413A2 (en) Proteins that bind angiogenesis-inhibiting proteins, compoisitions and methods of use thereof
CN105153308A (zh) 针对活化蛋白c的单克隆抗体
US20250109189A1 (en) Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
KR20130054953A (ko) 간질성 폐 질환을 치료하기 위한 인자 ｘｉｉ 억제제
DK2747776T3 (en) : RELATIONSHIPS TO USE IN INCREASING COAGULATION
CN118662635A (zh) 用于治疗和/或预防冠状病毒诱导的急性呼吸窘迫综合征的抑制masp-2的方法
TW202402790A (zh) 減少呼吸系統感染之方法
JP2009505979A (ja) アルツハイマー病の治療に使用するためのトランケート型メマプシン２
US20230002510A1 (en) Cela-1 inhibition for treatment of lung disease
CN106102772A (zh) 用于预防和/或治疗与dennd1a变体2相关疾病的组合物和方法
WO2021205150A1 (en) An enzyme
US20190352368A1 (en) Identification of novel anti-fibrotic peptide in c-terminal region of the met receptor tyrosine kinase
EP3102940B1 (en) Anti-metalloprotease antibody for diagnosis and treatment of cancers
EP3042667A1 (en) Dpp-4-targeting vaccine for treating diabetes
US9909108B2 (en) Preparations and methods for treating malignancies
JP2009539853A (ja) 抗プラスミン切断酵素の基質および阻害剤ならびにその使用
WO2006106599A1 (ja) 細胞外ドメインシェディングの異常亢進に起因する疾患の予防及び／又は治療のための医薬
WO2003084998A1 (fr) Anticorps monoclonal neutralisant la megsine
US20130084303A1 (en) Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
HK40107355A (zh) 用於抑制有需要的受试者的纤维化的方法
WO2024036192A2 (en) Compositions and methods for assessing the severity of and treating covid-19
HK40118775A (zh) 减少呼吸系统感染的方法
KR20140045345A (ko) 질환을 치료하고, 진단하고, 모니터링하기 위한 조성물과 방법

Legal Events

Date Code Title Description
SREP Specification republished